P/B
102,3
BeOne Medicines
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
$529.3B
Market Cap • 10/2/2026
2010
(16 years)
Founded
2016
(10 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
86,4
P/EBITDA
510,1
P/OCF
356,6
P/FCF
389,8
P/E
154,3
BVPS
3,5
EPS
2,3
Market Cap
Market Cap
529,3B
EV
526,2B
EV/Revenue
85,9
EV/EBITDA
507,2
EV/EBIT
570,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-7,9B
Profitability
Gross Margin
88,9%
EBITDA Margin
16,9%
EBIT Margin
15,1%
Net Margin
10,7%
D&A/EBITDA
0%
R&D/Revenue
37,4%
Capex/Revenue
2,1%
Capex/D&A
110,5%
Capex/OCF
8,5%
SBC/OCF
26,1%
% PPE
19,5%
% Goodwill
0%
ROE
14,7%
ROIC
27,5%
Growth
CAGR Revenue 5Y
45,3%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,4
Quick Ratio
2,9
Interest Coverage
152578%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!